The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff.
Please visit the COVID-19 & Cancer Resource Center where COVID-related content is freely available.
Trending - Altmetric
- Abstract 5133: TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidibLast mentioned on Wed Nov 03 2021
- Loss of long non-coding RNA NXTAR in prostate cancer augments androgen receptor expression and enzalutamide resistanceLast mentioned on Sun Nov 21 2021
- Lessons from Applied Ecology: Cancer Control Using an Evolutionary Double BindLast mentioned on Thu Nov 18 2021
- CRISPR/Cas9-induced DNA damage enriches for mutations in a p53-linked interactome: implications for CRISPR-based therapies.Last mentioned on Wed Nov 24 2021
- Free fatty acids rewire cancer metabolism in obesity-associated breast cancer via estrogen receptor and mTOR signalingLast mentioned on Wed Nov 17 2021
- See more
Advertisement
